A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of Bacillus Calmette-Guerin (BCG) or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenace BCG therapy
A trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment, or other standard treatment, for bladder cancer that has come back
HYMN: Now Open to Recruitment in centres across the UK
This trial is funded by Cancer Research UK, coordinated by the University of Birmingham CRUK- Clinical Trials Unit and sponsored by University College London.
Chief Investigator: Professor John Kelly, University College Hospital, London Trial Coordinator: Kathryn Matthews, Cancer Research UK Clinical Trials Unit, Institute for Cancer
Studies, University of Birmingham, Edgbaston, Birmingham, B15 2TT
A randomized controlled study comparing intravesical Synergo® System adjuvant hyperthermia treatment in
conjunction with Mitomycin C (LHT + MMC) versus BCG intravesical immunotherapy (BCG) adjuvant treatment
in patients with Superficial Transitional Cell Carcinoma of the Bladder (STCCB)
Medical Enterprises ongoing clinical study started in 2002. It is a randomized,
multi-center study. Urology departments in Hospitals from Italy, France, The
Netherlands, Belgium and Israel are participating in the study.
The clinical study Chief investigator is:
Prof J.A Witjes, Department of Urology, Radboud University Hospital,
Nijmegen, The Netherlands.
Study Participants:
Patients suffering from Non-Muscle invasive bladder cancer (Ta, T1 or CIS) after tumor removal by Surgery (TUR).
Intermediate to high risk for recurrence or progression.
No previous intra vesicle instillations of MMC in last 12 months, or BCG in last 24 months
